NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 237 filers reported holding NEKTAR THERAPEUTICS in Q1 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $20 | -85.1% | 34,167 | -85.4% | 0.00% | -100.0% |
Q2 2023 | $134 | -49.6% | 234,257 | -38.2% | 0.00% | -66.7% |
Q1 2023 | $266 | -72.0% | 379,117 | -9.8% | 0.00% | -76.9% |
Q4 2022 | $950 | -99.9% | 420,455 | +80.6% | 0.01% | +62.5% |
Q3 2022 | $744,000 | +72.6% | 232,805 | +105.2% | 0.01% | +60.0% |
Q2 2022 | $431,000 | -76.5% | 113,460 | -66.6% | 0.01% | -61.5% |
Q1 2022 | $1,832,000 | +224.2% | 339,914 | +980.1% | 0.01% | +333.3% |
Q3 2021 | $565,000 | +7.4% | 31,472 | +2.5% | 0.00% | -40.0% |
Q2 2021 | $526,000 | +11.0% | 30,692 | +29.3% | 0.01% | 0.0% |
Q1 2021 | $474,000 | +74.3% | 23,741 | +44.6% | 0.01% | -37.5% |
Q3 2020 | $272,000 | -33.8% | 16,421 | -7.6% | 0.01% | -33.3% |
Q2 2020 | $411,000 | +67.1% | 17,770 | +55.8% | 0.01% | +9.1% |
Q4 2019 | $246,000 | -4.3% | 11,404 | -19.3% | 0.01% | -8.3% |
Q3 2019 | $257,000 | -39.0% | 14,124 | +63.8% | 0.01% | -92.2% |
Q2 2018 | $421,000 | – | 8,625 | – | 0.15% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 432,952 | $1,385,000 | 0.91% |
GREAT POINT PARTNERS LLC | 447,820 | $1,433,000 | 0.34% |
Birchview Capital, LP | 128,000 | $410,000 | 0.29% |
Edgestream Partners, L.P. | 1,047,636 | $3,352,000 | 0.26% |
Rhenman & Partners Asset Management AB | 550,000 | $2,068,000 | 0.22% |
CM Management, LLC | 50,000 | $160,000 | 0.18% |
TANG CAPITAL MANAGEMENT LLC | 430,037 | $1,376,000 | 0.17% |
PDT Partners, LLC | 307,953 | $985,000 | 0.15% |
Virtus ETF Advisers LLC | 72,018 | $230,000 | 0.09% |
ALGERT GLOBAL LLC | 476,412 | $1,525,000 | 0.09% |